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Alzheimer disease (AD) is a complex disorder characterized by a wide range, within and between families, of ages
at onset of symptoms. Consideration of age at onset as a covariate in genetic-linkage studies may reduce genetic
heterogeneity and increase statistical power. Ordered-subsets analysis includes continuous covariates in linkage
analysis by rank ordering families by a covariate and summing LOD scores to find a subset giving a significantly
increased LOD score relative to the overall sample. We have analyzed data from 336 markers in 437 multiplex
(2 sampled individuals with AD) families included in a recent genomic screen for AD loci. To identify genetic
heterogeneity by age at onset, families were ordered by increasing and decreasing mean and minimum ages at onset.
Chromosomewide significance of increases in the LOD score in subsets relative to the overall sample was assessed
by permutation. A statistically significant increase in the nonparametric multipoint LOD score was observed on
chromosome 2q34, with a peak LOD score of 3.2 at D2S2944 ( ) in 31 families with a minimum age atPp .008
onset between 50 and 60 years. The LOD score in the chromosome 9p region previously linked to AD increased
to 4.6 at D9S741 ( ) in 334 families with minimum age at onset between 60 and 75 years. LOD scoresPp .01
were also significantly increased on chromosome 15q22: a peak LOD score of 2.8 ( ) was detected atPp .0004
D15S1507 (60 cM) in 38 families with minimum age at onset 79 years, and a peak LOD score of 3.1 (Pp
) was obtained at D15S153 (62 cM) in 43 families with mean age at onset 180 years. Thirty-one families.0006
were contained in both 15q22 subsets, indicating that these results are likely detecting the same locus. There is
little overlap in these subsets, underscoring the utility of age at onset as a marker of genetic heterogeneity. These
results indicate that linkage to chromosome 9p is strongest in late-onset AD and that regions on chromosome 2q34
and 15q22 are linked to early-onset AD and very-late-onset AD, respectively.
Introduction
Alzheimer disease (AD [MIM 104300]) is a neurode-
generative disorder that is the most common cause of
dementia in older adults. The etiology of AD is complex,
comprising both genetic and environmental factors. Four
genes are known to be associated with AD. Mutations
in three of these genes (amyloid precursor protein [APP],
presenilin 1 [PS1], and presenilin 2 [PS2]) cause auto-
somal dominant, early-onset familial AD (Goate et al.
1991; Levy-Lahad et al. 1995; Sherrington et al. 1995).
Together, these genes account for !2% of all cases of AD.
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The fourth gene, apolipoprotein E (APOE), increases risk
of the more common late-onset familial and sporadic
forms of AD. The APOE-4 allele increases risk and re-
duces age at onset of AD in a dose-dependent manner
(Corder et al. 1993, 1994; Saunders et al. 1993; Stritt-
matter et al. 1993). These genes were identified by study-
ing sets of families chosen by age at onset and inheritance
pattern. Age at onset is clearly an important covariate
for the identification of susceptibility genes for AD.
In addition to the relationship of these known genes
with age at onset of AD, several lines of evidence suggest
that age at onset may have other genetic determinants.
Segregation analysis of large pedigrees with AD suggested
that multiple loci associated with age at onset exist (Daw
et al. 2000). Quantitative trait linkage analysis, with age
at onset as the trait of interest, identified several genomic
regions that might contain genes modulating age at on-
set of AD symptoms (Li et al. 2002).
Although the identification of APP, PS1, PS2, and
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APOE has significantly advanced the understanding of
the etiology of AD, together these loci explain, at most,
50% of the genetic effect in the disease (Farrer 1997).
Several large families with early-onset familial AD have
been reported that do not have mutations in APP, PS1,
or PS2, indicating that at least one additional early-
onset AD gene exists (Janssen et al. 2003). Also, familial
aggregation of AD has been described in populations
with low frequency of the APOE-4 allele, indicating that
additional late-onset AD genes exist (Pericak-Vance et
al. 1996). Therefore, significant effort has been invested
in identifying additional susceptibility loci, particularly
for late-onset (age at onset 160 years) AD.
To this end, many genomic screens have been per-
formed in families with multiple individuals diagnosed
with late-onset AD (Pericak-Vance et al. 1997, 2000;
Kehoe et al. 1999; Hiltunen et al. 2001; Myers et al.
2002; Blacker et al. 2003; Farrer et al. 2003). Although
these studies have detected suggestive evidence for link-
age on many chromosomes, the strongest and most con-
sistent linkages across these studies were to regions of
chromosomes 9, 10, and 12. However, aside from con-
sidering late-onset AD separately (variously defined as
60 and 65 years old), these studies have not thor-
oughly considered linkage heterogeneity by age at onset.
Two recent studies (Olson et al. 2001, 2002) describe
analyses including age as a covariate in linkage analysis
of affected relative pairs. These studies report significant
differences in linkage on chromosomes 20 and 21 when
current age was used as the covariate, which was in-
terpreted as meaning that these loci influenced duration
of AD rather than age at onset.
Since the effects of all known AD loci have been
shown to be age dependent, the limited consideration
of age at onset may have low power to detect linkage
to loci with age-dependent effects on risk of AD. There-
fore, examination of genomic-screen data with consid-
eration of age at onset as a covariate may refine esti-
mates of linkage.
Several methods of incorporating covariates into link-
age analysis have been developed. The simplest to apply
is stratification of families into defined subsets according
to age at onset (Pericak-Vance et al. 1991). Blacker and
colleagues (2003) recently employed this approach,
classifying families as “late onset” if all affected indi-
viduals had onset of AD at age 65 years and “early/
mixed” if at least one individual was affected at onset
age !65 years. One disadvantage of this method is that
a predetermined cut point must be used for stratification
and may not result in the most homogeneous subsets.
For example, the APOE gene has its maximum effect
on risk of AD between the ages of 60 and 70 years;
therefore, a cut point of age 65 years might decrease
the power of the analysis to detect the APOE gene. An
alternative to stratification is ordered-subsets analysis
(OSA) (Hauser et al. 1998, in press; Ghosh et al. 2000;
Shao et al. 2003). OSA orders families by a continuous
covariate (such as mean age at onset) and then finds the
subset with maximum evidence for linkage to a particu-
lar map of markers. The statistical significance of the
increased evidence for linkage relative to evidence for
linkage in the entire sample is assessed via permutation.
This approach identifies a set of families in which the
LOD score in a particular region is higher than in the
overall data set. Thus, the primary goal of OSA is to
identify regions of increased linkage in a subset of fami-
lies, even though genetic heterogeneity significantly re-
duces the evidence for linkage in the overall data set.
Subsets identified by OSA may then be used for can-
didate-gene analysis and fine mapping in that region of
interest. OSA limits the possibility of missing such a
covariate-dependent linkage result because it adaptively
chooses the cut point for a stratified analysis on the
basis of the observed linkage evidence. We have applied
OSA to data from a recently completed genomic screen
in late-onset AD (Pericak-Vance et al. 2000) to identify
loci with increased evidence for linkage (relative to the
overall sample) in subsets of families defined by mean
and minimum ages at onset.
Subjects and Methods
Subjects
Families with two or more individuals with a diag-
nosis of probable or definite AD were ascertained by the
Collaborative Alzheimer Project (CAP [Duke University
Medical Center, Vanderbilt University Medical Center,
and University of California at Los Angeles]), the Na-
tional Institute of Mental Health (NIMH) AD Genetics
Initiative (Massachusetts General Hospital, Johns Hop-
kins University, and the University of Alabama at Bir-
mingham), and the Indiana University (IU) AD Cell Re-
pository. Informed consent was obtained for each
participant, under protocols approved by the institu-
tional review boards at the participating sites. The cur-
rent study was conducted under protocols approved by
the Duke University Medical Center institutional review
board. A subset of 437 white families with complete age-
at-onset information was selected from the original 455
families included in the genomic screen (Pericak-Vance
et al. 2000). Two Latino and three African American
families were removed from the original genomic screen
data set to control for potential linkage heterogeneity
by ethnicity; linkage results in regions of interest became
more significant when these families were removed (data
not shown). These 437 families contained 1,252 sampled
individuals (1,014 affected individuals), 543 affected sib-
ling pairs, and 62 other affected relative pairs.
The diagnosis of AD was consistent with National
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Institute of Neurological and Communicative Disorders
and Stroke–Alzheimer’s Disease and Related Disorders
Association consensus diagnostic criteria (McKhann et
al. 1984). Autopsy confirmation of the AD diagnosis,
by use of consensus criteria (Mirra et al. 1991; Hyman
and Trojanowski 1997), was obtained for at least one
individual with AD in 227 of the 437 (52%) families.
Age at onset of AD was recorded as that age at which
the first symptoms were noted by the participant or a
family member. The mean age at onset for individuals
with AD was 72.76.7 years (range 49–93 years). Two
covariates were used to divide the families into subsets,
mean age at onset and minimum age at onset. To examine
the notion that early onset, even in only one member of
the family, may be a marker for increased genetic suscep-
tibility in a given region of the genome, the minimum age
at onset was determined by the youngest age at onset in
each family. Use of minimum age at onset as a covariate
may therefore increase the power to detect a locus that
causes earlier-onset AD with wide intrafamilial variation
in age at onset, as is seen in families with PS2 mutations
(Sherrington et al. 1996).
Laboratory Analysis
Genomic DNA was extracted from whole blood by
use of the Puregene system (Gentra Systems) (for CAP
samples) or was obtained directly from repositories (for
NIMH and IU samples). Microsatellite-marker genotyp-
ing was performed for 336 markers by use of the FASST
method (Vance and Ben Othmane 1998). Markers were
selected on the basis of heterozygosity, ease of genotyp-
ing, and location, to generate a marker map of ∼10 cM
density.
Systematic genotyping errors were minimized by use
of a system of quality control (QC) checks with dupli-
cated samples (Rimmler et al. 1998). On each 96-well
PCR plate, two standard samples from CEPH families
were included, and six additional samples were dupli-
cates of samples either on that plate or on another plate
in the screen. Laboratory technicians were blinded to the
location of these QC samples to avoid bias in interpre-
tation of results. Automated computer scripts checked
each set of genotypes submitted by the technician for
mismatches between the duplicated samples; mismatches
were indicative of potential genotype reading errors,
misloading of samples, and sample misallocations. Mis-
matched reads were returned to the laboratory techni-
cian with a set of surrounding samples for rereading. As
an additional QC measure, potential pedigree errors were
checked with the program RELPAIR (Boehnke and Cox
1997), which infers likely relationships between pairs of
relatives, using identity-by-descent sharing estimates from
a set of microsatellite markers.
Statistical Analysis
The affected relative pair–allele-sharing method imple-
mented in the ASM module of GENEHUNTER-PLUS
(Kong and Cox 1997) was used to calculate multipoint
nonparametric LOD scores with the Spairs statistic and a
linear model. Intermarker distances were obtained from
the genetic linkage maps developed by Marshfield Medi-
cal Research Foundation (Broman et al. 1998).
The OSA program (Hauser et al. 1998, in press) was
used to identify significant increases in multipoint non-
parametric LOD score curves in subsets of families de-
fined by mean and minimum ages at onset. The OSA
method proceeds as follows:
1. Order families by a family-specific covariate value.
2. Assign ranks to each family in ascending and de-
scending order. Families with the same covariate
value are given the same rank.
3. Beginning with the first-ranked families, calculate
the multipoint LOD scores for the subset across all
map positions for a chromosome. Store the maxi-
mum LOD score and map position.
4. Add the family (or families) next in order after the
previous subset (e.g., 12). Calculate the multi-
point LOD scores. Store the maximum LOD score
and map position. Consider successively larger sub-
sets by repeating this step (e.g., 123, 123
4,…), adding the remaining families in order until
all families are included in the final subset (i.e.,
).1…N
5. Select the subset with the highest maximum LOD
score.
6. Perform permutation tests of the chromosomewide
significance of the increase in this maximum LOD
score over baseline:
A. Randomly order families with the same num-
ber of ranks as in step 2.
B. Repeat steps 3–5.
C. Determine if the subset generates a multipoint
LOD score anywhere on the chromosome at
least as high as the maximum subset LOD
score found in step 5.
D. Repeat 10,000 times.
E. Calculate an empirical P value on the basis of
the proportion of 10,000 random orderings
of families that gave a maximum subset LOD
score greater than that seen in step 5.
7. Repeat the procedure for each covariate and rank-
ing order (ascending and descending).
In addition, the “optimal slice” option was used to
define the subset (of any size) of adjacent families from
anywhere in the covariate distribution that maximized
the LOD score. This option follows the procedure out-
lined above but repeats the process beginning with suc-
cessively higher ranks (e.g., start with the second rank,
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Table 1
Significant Increases in LOD Score Associated with Age at Onset, Detected by OSA in the Overall Data Set
Chromosome
and Peak Marker cM
Max
LOD
Change
from Baseline P
No. of Families
in Subseta Variableb Order
Age
(years)
2q34:
D2S2944 210 3.0 3.0 .002 32 Minimum Ascending 60
D2S2944 210 3.2 3.2 .008 31 Minimum Optimal slice 50–60
9p22:
D9S741 42 4.6 1.6 .01 334 Minimum Optimal slice 60–75
15q22:
D15S1507 60 2.8 2.8 .0004 38 Minimum Descending 79
D15S1507 60 2.8 2.8 .004 38 Minimum Optimal slice 79
D15S153 62 3.1 3.1 .0006 43 Mean Descending 80
D15S153 62 3.1 3.1 .01 43 Mean Optimal slice 80
a .np 437
b Age at onset.
then the third rank, etc.). The optimal-slice analysis con-
siders a much greater number of potential subsets than
the other two rank orders. Therefore, if the same subset
of families is identified in the ascending or descending
orders and the optimal-slice option, the optimal-slice sub-
set may have a larger P value than the other analyses.
For each chromosome, six maximum nonparametric
LOD scores were obtained. To adjust for the use of two
covariates (minimum and mean ages at onset) and two
independent ranking orders (ascending and descending),
a nominal significance level of 0.0125 (0.05/4) was used.
As OSA results for the optimal-slice option are highly
correlated with those for ascending and descending rank-
ings, no correction was made for the optimal-slice analy-
sis. Since analysis was performed on 23 chromosomes,
results with P values !.0005 (.0125/23) may be consid-
ered as having genomewide significance. Clinical features
for each subset with a statistically significant increase in
nonparametric LOD score were analyzed using SAS ver-
sion 8 (SAS Institute).
To assess the potential modification of linkage by
APOE genotype in OSA-defined subsets, the ASM mod-
ule of GENEHUNTER-PLUS (Kong and Cox 1997) was
used to generate nonparametric LOD scores in OSA sub-
sets weighted by APOE-4 carrier status. Increases in LOD
scores when weighting by the proportion carrying the
APOE-4 allele indicates epistasis, whereas increases when
weighting by the proportion not carrying an APOE-4 al-
lele indicates linkage heterogeneity.
Results
Nominally significant increases in LOD scores were ob-
served in three regions of the genome, on chromosomes
2q34, 9p22, and 15q22 (table 1). When ordering fami-
lies by ascending minimum age at onset, a maximum LOD
score of 3.0 was obtained at D2S2944 (210 cM) in the
32 families with minimum age at onset 60 years. This
was a significant increase from the baseline LOD score
of 0 ( ). The optimal slice identified for this re-Pp .002
gion was 31 families with minimum age at onset of 50–
60 years; the maximum LOD score was 3.2 at D2S2944
( ). The 1-LOD–unit down support interval (SI)Pp .008
for this peak is 46 cM wide, from 193 cM to 239 cM
(fig. 1).
Consistent with the original genomic screen analysis
(Pericak-Vance et al. 2000), the region on 9p22 generated
strong evidence for linkage in the overall data set
( ). Although neither the ascending nor de-LODp 3.0
scending orders generated a significant increase in the
LOD score, the optimal-slice ranking by minimum age
at onset generated a maximum LOD score of 4.6 at
D9S741 ( ) in the 334 families with minimum agePp .01
at onset between 60 and 75 years. The 1-LOD–unit
down SI for this peak is 15 cM wide, from 33 cM to
48 cM (fig. 2).
When descending minimum age at onset was consid-
ered as the covariate, a maximum LOD score of 2.8
was obtained at D15S1507 (60 cM) in the 38 families
with minimum age at onset 79 years. This was also
a significant increase from the baseline LOD score of 0
( ). The same 38 families were identified as thePp .0004
optimal slice for this covariate. The 1-LOD–unit down
SI for this peak was 21 cM wide, from 51 cM to 72 cM
(fig. 3).
Similarly, when considering family mean age at onset
as the covariate, a maximum LOD score of 3.1 was ob-
tained at D15S153 (62 cM) in the 43 families with mean
age at onset 80 years ( ). The optimal slicePp .0006
consisted of the same 43 families; however, the P value
for this subset was much less significant ( ), owingPp .01
to the greater number of subsets considered in the op-
timal-slice analysis. The 1-LOD–unit down SI for this
region is 14 cM wide, from 56 cM to 70 cM (fig. 3).
The two chromosome 15 regions overlap significantly.
Both subsets contain 31 of the same families, and the SI
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Figure 1 Nonparametric LOD score plot for chromosome 2. LOD scores for the overall sample ( [solid line]) and the subsetnp 437
with minimum age at onset with a range of 50–60 years ( [dashed line]) are presented. The 1-LOD–unit down SI (192–239 cM) isnp 31
marked by the bold horizontal line.
for the descending mean age-at-onset peak is completely
contained within the SI for the descending minimum–age
at onset peak. The peak markers (D15S1507 and
D15S153) are only 2 cM apart. Thus, these two results
point to the same very-late-onset AD locus on 15q22 in
a subset of 50 families.
A description of these subsets by family size, origin
of data set (CAP, IU, and NIMH), age at onset, and
APOE-4 carrier status is provided in table 2. There is
some overlap between the subsets of families linked to
the three regions: the chromosome 2q and 15q subsets
do not overlap at all, three families are in both the chro-
mosome 9p and 15q subsets, and 13 families are in both
the 2q and 9p subsets. A greater percentage (19%) of
the 31 families in the 2q34 subset were “extended fam-
ilies” (defined as “those families with sampled affected
relative pairs other than sibling pairs”), compared with
the overall data set (6%). In addition, this subset con-
tained a higher proportion of families from the CAP
(18%) and IU (12%) data sets, compared with the NIMH
data set (3%). This is perhaps because the publicly dis-
tributed NIMH data set is composed primarily of fami-
lies containing affected sibling pairs, with few other
affected-relative pairs available. It is not surprising that
this subset had an earlier mean age at onset (66.1 years)
than did the overall data set (72.7 years), but the range
of age at onset was not substantially different. The mean
within-family difference was greater in this subset than
overall (14.8 years vs. 6.7 years), indicating that age at
onset is more variable within families in this subset. The
proportion of families in which all affected individuals
had at least one copy of the APOE-4 allele was higher
in this subset (71%) than overall (61%).
In contrast, the families in the 15q22 subset contained,
almost exclusively, affected sibling pairs (2% extended
families), had substantially later age at onset than the
overall data set (and had a smaller within-family differ-
ence and range of age at onset), and included a much
lower proportion of families in which all affected indi-
viduals carried the APOE-4 allele (34% vs. 61%). This
subset contained a slightly greater percentage of families
from the NIMH data set (14%), compared with the CAP
(9%) and IU (6%) data sets. The 9p22 subset contained
similar proportions of families from all three data sets
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Figure 2 Nonparametric LOD score plot for chromosome 9. LOD scores for the overall sample ( [solid line]) and the subsetnp 437
with minimum age at onset with a range of 60–75 years ( [dashed line]) are presented. The 1-LOD–unit down SI (33–48 cM) is markednp 32
by the bold horizontal line.
and was not substantially different from the overall sam-
ple, with respect to percentage of extended families,
APOE genotype, or within-family differences in age at
onset.
To test if linkage in these three regions is modified by
the APOE genotype, conditional linkage analysis was
performed using GENEHUNTER-PLUS. Weighted non-
parametric LOD scores were calculated for each OSA
subset by weighting family-specific LOD scores by the
proportion of affected members carrying an APOE-4
allele (to model epistasis) and by the proportion of af-
fected members not carrying an APOE-4 allele (to model
heterogeneity). No significant increases in the LOD score
were seen for any subset, indicating that evidence for
linkage to these regions is not strongly modified by the
APOE genotype.
Discussion
We have identified three regions with age-dependent evi-
dence for linkage to AD: a locus on chromosome 2q34
associated with earlier onset, a locus on 9p associated
with late onset, and a locus on 15q22 associated with
very late onset. To our knowledge, the 2q34 locus has
not been reported elsewhere. The 9p locus was detected
in the original genomic screen in these families (Pericak-
Vance et al. 2000). The region on 15q22 is ∼20 cM from
D15S659, a marker at which a Finnish case-control study
detected linkage disequilibrium with AD (Hiltunen et al.
2001). Neither of the genomic screens that considered
age at onset, in some fashion, as a covariate (Olson et
al. 2002; Blacker et al. 2003) detected linkage to any of
these regions. This is surprising, since 39 of 50 families
in the 15q subset were from the NIMH family data set
common to this study and to the studies by Olson et al.
(2002) and Blacker et al. (2003). The current study did
not detect significant improvement in linkage results in
families with “early/mixed” onset AD (families with a
minimum age at onset !65 years) in any of the six “early/
mixed” regions (1p31, 3p26, 10p14, 14q22, 15q26, or
19q13) reported by Blacker and colleagues (2003). Simi-
larly, this study did not identify linkage of very-late-onset
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Figure 3 Nonparametric LOD score plot for chromosome 15. LOD scores for the overall sample ( [solid line]), the subset withnp 437
minimum age at onset 179 years ( [dashed line]), and the subset with mean age at onset 180 years ( [dotted line]) are presented.np 38 np 43
The 1-LOD–unit down SIs for the minimum–age-at-onset curve (51–72 cM) and the mean age at onset curve (56–70 cM) are marked by the
bold horizontal lines.
AD to chromosomes 20 and 21, as others have reported
elsewhere (Olson et al. 2001, 2002). Therefore, either
the composition of the current data set or the specific
manner in which OSA incorporates covariates into link-
age analysis has resulted in the novel results.
To explore this issue further, we used OSA to reanalyze
the data from chromosomes 20 and 21 in the subset of
275 families in this study collected by the NIMH AD
Genetics Initiative. No significant differences in LOD
score were detected on chromosome 21 by minimum or
mean age at onset. The variation in results on chromo-
some 21 may be due to differences in methodology, since
OSA utilizes family-specific covariates, and the likeli-
hood-ratio methods used by Olson et al. (2001) utilize
relative pair–specific covariates. In contrast, a significant
increase in LOD score at 12 cM ( ;LODp 2.6 Pp
) was detected on chromosome 20 in the 61 families.002
with mean age at onset 78 years. This result is 12 cM
from the peak LOD score reported by Olson et al.
(2002) and suggests that variation in chromosome 20
linkage results in very-late-onset AD may be due to dif-
ferences in the composition of the family data sets used
rather than differences in statistical methodologies.
However, as expected from our overall results, the non-
NIMH families showed no increase in LOD scores in
this region.
These results illustrate the utility of OSA for incor-
porating continuous covariates into linkage analysis of
complex traits. OSA avoids arbitrary cut points (such
as early/mixed versus late onset, defined as “age at onset
60 or 65 years”) by considering the entire distribution
of the covariate. This approach identifies loci that may
be strongly linked to disease in a small portion of the
covariate distribution. Controlling for the covariate on
the family level rather than the relative-pair level focuses
on identifying between-family linkage heterogeneity due
to the covariate and identifies a subset of families to use
in fine-mapping or candidate-gene studies.
OSA analysis detected a significant increase in LOD
score (3.2) on chromosome 2q34 in 31 families with
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Table 2
Clinical Features of Subsets Identified by OSA
REGION
NO. (%) OF FAMILIES IN SAMPLE
%
EXTENDED
MEAN
AGE
AT
ONSET RANGE
MEAN
WITHIN-
FAMILY
DIFFERENCE
IN AGE AT
ONSET RANGE
FAMILIES
POSITIVE
FOR
APOE-4a
(%)Total CAP IU NIMH
2q34 31 (7) 10 (18) 13 (12) 8 (3) 19 66.1 50–85 14.8 6–35 71
9p22 334 (76) 45 (79) 77 (73) 212 (77) 6 71.5 60–88 7.0 0–22 65
15q22 50 (11) 5 (9) 6 (6) 39 (14) 2 82.2 74–93 4.5 0–13 34
Total 437 (100) 57 (100) 105 (100) 275 (100) 6 72.7 49–93 6.7 0–35 61
a Families in which all affected individuals have at least one copy of the APOE-4 allele.
minimum age at onset between 50 and 60 years. To our
knowledge, no previous study has reported significant
evidence for linkage within 50 cM of this peak. These
families (mean age at onset 66 years; range 50–85 years)
all contained at least one individual with early-onset
AD (age at onset 60 years) and at least one individual
with late-onset AD (age at onset 160 years). The within-
family difference in age at onset was larger than that in
the overall sample (14.8 years vs. 6.7 years), suggesting
that there was more variability in age at onset in this
subset. Thus, this region may contain a locus, like PS2,
that causes AD in families with both early- and late-
onset cases of AD and is marked by wide variability in
the age at onset of symptoms (Sherrington et al. 1996).
Furthermore, a greater proportion of families (19% vs.
6%) contained an affected relative pair other than a
sibling pair, indicating that this locus may be associated
with a family history of AD in multiple generations.
Whereas all individuals with AD carried the APOE-4
allele in a greater proportion of families in this subset
(72%) versus the overall data set (61%), there was no
modification of the linkage results when conditioning
on the APOE genotype.
A search of the Ensembl database identified 454
known genes in the 1-LOD–unit down SI (192–239 cM)
for this locus. Two genes are of particular interest: mi-
crotubule-associated protein 2 (MAP2) and ATP-binding
cassette A12 (ABCA12). MAP2 is located within 4 Mb
of the peak marker, D2S2944. MAP2 is a dendrite-spe-
cific microtubule-binding protein from the same protein
family as microtubule-associated protein t (MAPT),
which is found in the characteristic neurofibrillary tangles
seen in the brains of patients with AD (Al-Bassam et al.
2002). The ABCA12 gene, located !1 Mb from the peak
marker, is a member of the ATP–binding cassette (ABC)
transporter superfamily, the members of which move sub-
strates across membranes. Other members of the ABCA
gene family have been implicated in disorders of choles-
terol transport (ABCA1) and early-onset forms of macu-
lar degeneration (ABCA4) (Dean et al. 2001). Since AD
is a neurodegenerative condition and the risk of AD is
influenced by other genes involved in cholesterol trans-
port (APOE), ABCA12 is a plausible candidate gene.
Farther away from the peak marker, but still in the SI,
are the genes for caspases 8 and 10 (involved in ap-
optosis) and the GTPase regulator alsin, mutations of
which have been recently reported in juvenile amy-
otropic lateral sclerosis (Hadano et al. 2001; Yang et
al. 2001).
OSA analysis also increased the LOD score in the re-
gion of chromosome 9p that provided the strongest evi-
dence for linkage in the original genomic screen (Peri-
cak-Vance et al. 2000) and subsequent studies in inde-
pendent samples (Farrer et al. 2003). A subset of 334
families with minimum age at onset between 60 and 75
years was identified using the optimal-slice option, and
the LOD score increased from a baseline of 3.0 to 4.6.
Mean age at onset, proportion of extended families, and
proportion of families with APOE-4 were all similar to
those in the overall sample. These results indicate that
this region influences the development of AD in a broad
subset of families with late-onset AD, and they narrow
the linkage to a 15-cM 1-LOD–unit down SI. According
to Ensembl, this interval contains 44 genes, including
several biologically plausible candidate genes for AD in
this data set—such as MTAP, p15, and p16—that are
currently being evaluated for association (Xu et al. 2002).
The other significant increase in LOD score, when con-
trolling for age at onset, was on chromosome 15q22.
The greatest evidence for linkage ( ) was de-LODp 3.1
tected in 43 families with mean age at onset 80 years,
and the P value for this increase met our criteria for
genomewide significance ( ). A similar increaseP ! .0005
was detected when minimum age at onset was used as
the covariate. These results suggest that the effect of this
locus is greatest in families with the oldest age at onset.
These subsets contained families consisting mostly of
affected sibling pairs, suggesting that this locus is in-
volved in causing AD in smaller family aggregates. Al-
though a larger proportion of families had at least one
individual with AD who did not carry the APOE-4 al-
lele, relative to the overall sample, there was no statis-
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tically significant modification of linkage results by the
APOE genotype. These observations regarding family
size and APOE genotype are consistent with the average
age at onset in this subset: multiple family members need
to survive past age 80 years to develop very-late-onset
AD, and APOE-4 has its maximum impact on risk of
AD between ages 60 and 70 years. Only one previous
study has reported evidence for linkage to this region.
Hiltunen et al. (2001) detected evidence for linkage dis-
equilibrium between late-onset AD and a marker ∼20
cM from the peak markers in the 15q22 region reported
here. The influence of age at onset and APOE genotype
on the linkage disequilibrium in the Finnish sample was
not reported; therefore, it is not possible to determine if
the previous association was stronger in very-late-onset
AD.
The 1-LOD–unit down SI for the mean age at onset
peak on 15q22 was completely contained in the SI for
the minimum age-at-onset peak. This 21-Mb SI contains
183 known genes, according to the Ensembl database.
Interesting candidate genes in this interval include:
MAP2K1 and MAP2K5, which encode protein kinases
that may influence apoptosis; RAB11A, which encodes
an RAS-related GTPase; KIF23, which enclodes a kine-
sinlike microtubule motor protein; and CYP1A2 and
CYP1A1, members of the cytochrome P450 gene family.
No other nominally significant ( ) increasesP ! .0125
in LOD score, when controlling for age at onset, were
detected in this data set. Genomic screens, reported else-
where, of families included in this data set detected evi-
dence for linkage to chromosomes 19 (Pericak-Vance et
al. 1991), 12 (Pericak-Vance et al. 1997), and 10 (Peri-
cak-Vance et al. 2000); however, evidence for linkage to
these regions did not significantly increase when age at
onset was considered. This could be because OSA has
reduced power to detect small increases in regions with
strong baseline LOD scores, since such strong overall
results may reflect an effect spread across much of the
age-at-onset distribution. Also, the analysis performed
here focused on the effect of one continuous covariate
(age at onset) on linkage; other categorical covariates—
such as APOE genotype, autopsy confirmation, and
source of data (CAP, IU, or NIMH)—could not be easily
incorporated in the analysis. On chromosome 10, the
maximum subset LOD score was 1.8 (from 0.6 overall),
and, on chromosome 12, the maximum subset LOD
score was 1.0 (from 0.22). It is important to note that
this OSA analysis did not consider the known effect of
the APOE genotype on linkage to chromosome 12
(where linkage is strongest in APOE-4–negative families).
However, the LOD score on chromosome 19q13 (near
APOE) increased to 3.4 (from 1.8) in 103 families with
mean age at onset !70 years. These results, although
not statistically significant relative to the linkage results
in the entire data set, indicate that the strongest linkage
in this region is in families with age at onset !70 years
of age; this is consistent with the known age-related
effect of the APOE-4 allele.
These results suggest that OSA is most powerful for
identifying genetic effects that are restricted to a small
subset of families with extreme covariate values; such
effects are likely to be lost in the overall sample because
of the substantial heterogeneity of the LOD scores. In
contrast, linkage signals that may be detected in the over-
all sample may be derived from a much larger set of
families, and a “ceiling effect” may exist. Therefore, the
improvement in LOD score when considering a covari-
ate may not be statistically significant in regions with
strong baseline linkage results.
These results also differ significantly from our study
of age at onset as a quantitative trait locus (QTL) in this
same data set (Li et al. 2002). The study of Li et al. (2002)
reported strong evidence for linkage ( ) of age atLOD 1 2
onset to regions of chromosomes 4q, 8q, and 10q. None
of these regions was detected by our analysis using AD
as the trait and age at onset as a covariate. Similarly,
quantitative linkage analysis of age at onset as the trait
did not detect evidence for linkage to 2q or 15q (Li et
al. 2002). This disparity in results reflects the differences
in the statistical methodology used in the two studies.
Analysis of age at onset as a QTL aims to identify ge-
netic loci that explain within- and between-family var-
iation in age at onset across the entire age-at-onset dis-
tribution. In contrast, OSA–LOD score analysis aims to
identify genetic loci that have stronger effects in subsets
of families defined by a continuous covariate. Although
the two methods have common goals (identifying genes
related to risk of AD), the approaches may detect loci
with different mechanisms of action.
The results of this study underscore the utility of using
covariate analyses to identify potential linkage hetero-
geneity in genomic screens of complex diseases. In AD,
age at onset is clearly an important covariate, because
each of the four known genes for AD has a distinctive
age-at-onset distribution. Although the effect of the lo-
cus on 9p was broad enough to be detectable in the
overall data set, the LOD score improves when consid-
ering a large subset of families with onset of AD between
ages 60 and 75 years. The two novel regions identified
in this study generate strong evidence for linkage only
in a small subset of families with extreme values of age
at onset. If candidate-gene analysis in these regions is
focused on families and individuals with extreme age at
onset, it is possible to maximize the chances of identi-
fyings the genes responsible for these linkages. Although
the percentage of cases of AD attributable to these loci
might be relatively small, the discovery of additional
genes that influence risk of AD would greatly advance
the understanding of the pathophysiology of the disease.
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